This study has two parts. Part A enrolls patients who have been diagnosed with a solid tumor, lymphoma or desmoid tumor that has either come back ("relapsed") or does not respond to therapy ("is refractory").
CHOP in collaboration with AbbVie, is conducting a study for pediatric patients from 1 year of age to 25 years of age with relapsed or refractory aggressive mature B-cell neoplasms (including diffuse large B-cell lymphoma, Burkitt and Burkitt-like lymphoma/leukemia).
This week’s In the News highlights PolicyLab’s second annual Impact Report, an FDA approval based on CHOP research, and a link between daycare and chronic lung disease effects in premature infants.
The overall goals of this study are to evaluate the side effects and benefits of CUDC-907 in patients with relapsed or treatment refractory solid tumor, brain tumor, or lymphoma, and to determine the best dose of CUDC-907 for children and adolescents.
The goals of research in the Bassing Lab are to elucidate the genetic, epigenetic, and biochemical mechanisms by which mammals develop their immune systems while suppressing autoimmunity and genomic aberrations that cause leukemia or lymphoma.
Yesterday, CBS Sunday Morning featured a story on the anaplastic lymphoma kinase, or ALK, clinical trial for lymphoma and neuroblastoma and CHOP’s partnership with the Alex's Lemonade Stand Foundation, which supported the basic research.
